Click here for helpful COVID-19 resources
MONJUVI Patient Site
My MISSION Support Link to MONJUVI Patient Website
  • Home
  • Enroll
  • Understanding Insurance
  • Financial Assistance
  • Resources
    Advocacy Groups & Societies Patient & Caregiver Education
  • MONJUVI Patient Site
Link to MONJUVI Patient Website

Site map

  • Home
  • Enroll
  • Understanding Insurance
  • Financial Assistance

  • Resources

  • Advocacy Groups & Societies
  • Patient & Caregiver Education
  • COVID-19 Resources
  • MONJUVI Patient Site
  • Terms of Use
  • Privacy Policy
  • MorphoSys
  • Incyte

IMPORTANT SAFETY INFORMATION

Important information I should know, including possible side effects, about MONJUVI:

MONJUVI may cause serious side effects, including infusion-related reactions, low blood cell counts, and infections.

The most common side effects of MONJUVI include feeling tired or weak, diarrhea, cough, fever, swelling of lower legs or hands, respiratory tract infection, and decreased appetite.

These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.

Before receiving MONJUVI, tell your healthcare provider about all your medical conditions, including if you have an active infection or have had one recently, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You should not become pregnant or breastfeed during treatment with MONJUVI and should use an effective method of birth control (contraception) and not breastfeed during and for at least 3 months after your last dose of MONJUVI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI. Refer to the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to MORPHOSYS US INC. at (844) 667-1992.

Please see the full Prescribing Information, including Patient Information, for additional Important Safety Information.

What is MONJUVI?

MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.

It is not known if MONJUVI is safe and effective in children.

The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI.

Link to Morphosys WebsiteLink to Incyte Website
Contact Us Terms of Use Privacy Policy Site Map
Link to Morphosys WebsiteLink to Incyte Website

MONJUVI and the MONJUVI logo are registered trademarks of MorphoSys AG.

© 2021

September 2021 RC-US-TAF-01161

 

Distributed and marketed by MorphoSys US Inc. and marketed by Incyte Corp.

MorphoSys is a registered trademark of MorphoSys AG.

Incyte and the Incyte logo are registered trademarks of Incyte Corp.

Expand

IMPORTANT SAFETY INFORMATION

Important information I should know, including possible side effects, about MONJUVI:

MONJUVI may cause serious side effects, including infusion-related reactions, low blood cell counts, and infections.

The most common side effects of MONJUVI include feeling tired or weak, diarrhea, cough, fever, swelling of lower legs or hands, respiratory tract infection, and decreased appetite.

These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.

Before receiving MONJUVI, tell your healthcare provider about all your medical conditions, including if you have an active infection or have had one recently, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You should not become pregnant or breastfeed during treatment with MONJUVI and should use an effective method of birth control (contraception) and not breastfeed during and for at least 3 months after your last dose of MONJUVI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI. Refer to the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to MORPHOSYS US INC. at (844) 667-1992.

Please see the full Prescribing Information, including Patient Information, for additional Important Safety Information.

What is MONJUVI?

MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.

It is not known if MONJUVI is safe and effective in children.

The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI.

Link to Morphosys WebsiteLink to Incyte Website
Contact Us Terms of Use Privacy Policy Site Map
Link to Morphosys WebsiteLink to Incyte Website

MONJUVI and the MONJUVI logo are registered trademarks of MorphoSys AG.

© 2021

September 2021 RC-US-TAF-01161

 

Distributed and marketed by MorphoSys US Inc. and marketed by Incyte Corp.

MorphoSys is a registered trademark of MorphoSys AG.

Incyte and the Incyte logo are registered trademarks of Incyte Corp.

You are now leaving My MISSION Support

You are now leaving this site and moving to an external website independently operated and not managed by MorphoSys. MorphoSys assumes no responsibility for the site.

If you would like to continue to the site, select "OK." If you do not wish to leave this site, select "Cancel."

OK Cancel
You are now leaving My MISSION Support

You are now leaving this site and moving to an external website independently operated and not managed by MorphoSys. MorphoSys assumes no responsibility for the site.

If you would like to continue to the site, select "OK." If you do not wish to leave this site, select "Cancel."

OK Cancel

For any questions on MY MISSION support or program enrollment, please call:

855-421-6172

Monday to Friday, 8 AM to 8 PM ET

The My MISSION Support Commercial Copay Assistance Program—Terms & Conditions

To receive benefits under the Copay Assistance Program, the patient must enroll in the My MISSION Support Copay Assistance Program and be accepted as eligible.

  • Patient must have private/commercial health insurance that provides coverage for the cost of MONJUVI® (tafasitamab‑cxix) under a medical benefit plan.
  • The Copay Assistance Program is not valid for patients covered, in whole or in part, under Medicaid (including Medicaid patients enrolled in a qualified health plan purchased through a health insurance exchange [marketplace] established by a state government or the federal government), Medicare, a Medicare Part D or Medicare Advantage plan (regardless of whether a specific prescription is covered), TRICARE, CHAMPUS, Puerto Rico Government Health Insurance Plan (“Healthcare Reform”), or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program (collectively, “Government Programs”).
  • The Copay Assistance Program is not valid for uninsured patients.
  • Patient must have an out-of-pocket cost for MONJUVI and be administered MONJUVI prior to the expiration date of the Copay Assistance Program. The benefit available under the Copay Assistance Program is valid for the patient's out-of-pocket cost for MONJUVI only. It is not valid for any other out-of-pocket costs (for example, office visit charges or medication administration charges) even if such costs are associated with the administration of MONJUVI. A claim for MONJUVI must be submitted by the provider to patient's private health insurance separately from any other services and products.
  • Eligible patients will pay $0 of copay per administration of MONJUVI. The benefit available under the Copay Assistance Program is limited to the amount the patient's private health insurance company indicates on the Explanation of Benefits (EOB) that the patient is obligated to pay for MONJUVI up to an annual maximum. The maximum Copay Assistance Program benefit per patient, per calendar year (January 1 through December 31), is $25,000. Enrolled patients are responsible for all copays and any other balances not covered by the Copay Assistance Program.
  • An Explanation of Benefits (EOB) from patient's private health insurance must be submitted within 180 days of the date of administration for the patient to receive any applicable copay assistance benefit; provided, however, that no EOB may be submitted more than 180 days after the expiration date of Copay Assistance Program. The EOB must reflect the patient's out-of-pocket cost for MONJUVI and submission of the claim by the patient's provider for the cost of MONJUVI.
  • Patient and provider agree not to seek reimbursement for all or any part of the benefit received by the patient through the Copay Assistance Program. Patient and provider are responsible for reporting receipt of Copay Assistance Program benefits to any insurer, health plan, or other third party who pays for or reimburses any part of the medication cost paid for by the Copay Assistance Program, as may be required.
  • Patient must be a resident of the United States or the Commonwealth of Puerto Rico. Product must originate and be administered to patient in the United States or the Commonwealth of Puerto Rico.
  • The Copay Assistance Program may apply to patient out-of-pocket costs incurred for MONJUVI within 180 days prior to the date patient is enrolled in the Copay Assistance Program, subject to annual Program maximum and the applicable Terms and Conditions based on MONJUVI administration date. Patient or provider may contact My MISSION Support for more information.
  • No other purchase is necessary.
  • The Copay Assistance Program is not insurance. If your insurance status changes, you must notify My MISSION Support immediately.
  • The Copay Assistance Program is void where prohibited by law, taxed, or restricted. The Copay Assistance Program is not transferable. No substitutions are permitted.
  • The Copay Assistance Program benefit cannot be combined with any other Copay Assistance Program, free trial, discount, prescription savings card, or other offer.
  • If acquiring MONJUVI from a Specialty Pharmacy (to be later administered in a physician office or outpatient institution), additional documentation may be required.
  • MorphoSys reserves the right to rescind, revoke, or amend the Copay Assistance Program at any time without notice.
  • The Copay Assistance Program is not contingent on any past or commercial sale of any MONJUVI.
  • The Copay Assistance Program does not assist with inpatient hospital claims, or in any bundled payment arrangement where there is no separate patient copay for MONJUVI, and does not assist with healthcare premiums.
  • These Terms and Conditions are valid for MONJUVI administered between July 31, 2020, and December 31, 2021.
COVID-19 Resources
Link to American cancer society
Visit American Cancer Society 
Link to Cancer care
Visit CancerCare 
Link to Cancer support community
Visit Cancer Support Community 
Link to Coa patient advocacy network
Visit Community Oncology Alliance
Link to Leukemia and lymphoma society
Visit Leukemia & Lymphoma Society
Link to Lymphoma research foundation
Visit Lymphoma Research Foundation
Link to National coalition for cancer survivorship
Visit National Coalition for Cancer Survivorship 
Link to National Comprehensive Cancer Network
Visit NCCN